IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells

Min Wu,Lin Zhang,Lifu Pi,Layang Liu,Siyu Wang,Yujie Wu,Hongli Pan,Mingyao Liu,Zhengfang Yi
DOI: https://doi.org/10.1007/s13402-024-00961-7
IF: 7.051
2024-06-19
Cellular Oncology
Abstract:Breast cancer is the most commonly diagnosed cancer in women, and triple-negative breast cancer (TNBC) accounts for approximately 15%-20% of all breast cancers. TNBC is highly invasive and malignant. Due to the lack of relevant receptor markers, the prognosis of TNBC is poor and the five-year survival rate is low. Paclitaxel is the first-line drug for the treatment of TNBC, which can inhibit cell mitosis. However, many patients develop drug resistance during treatment, leading to chemotherapy failure. Therefore, finding new therapeutic combinations to overcome TNBC drug resistance can provide new strategies for improving the survival rate of TNBC patients.
oncology,pathology,cell biology
What problem does this paper attempt to address?